查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1997316

腸道疾病檢測市場：2026-2032年全球市場預測（依檢測方法、產品類型、病原體、檢體類型、最終用戶和通路分類）

Enteric Disease Testing Market by Test Method, Product Type, Pathogen, Sample Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，腸道疾病檢測市場價值將達到 42.9 億美元，到 2026 年將成長至 46.2 億美元，到 2032 年將達到 74.9 億美元，複合年成長率為 8.29%。

主要市場統計數據
基準年 2025 42.9億美元
預計年份：2026年 46.2億美元
預測年份 2032 74.9億美元
複合年成長率 (%) 8.29%

全面概述不斷發展的腸道疾病檢測領域，其中技術、法規和臨床需求相互交織，共同塑造診斷策略。

腸道感染疾病檢測的驅動力在於快速發現並應對細菌、病毒和寄生蟲引起的疫情，這使其處於臨床緊迫性和技術創新的交匯點。診斷檢查室、醫院、研究機構和學術中心正依賴日益多樣化的生物化學檢驗、培養、免疫檢測、分子診斷和定序技術。同時，不斷發展的法律規範、不斷變化的醫療保健環境以及變革性的患者診療路徑正在重塑檢測的檢驗、應用和整合到常規工作流程中的方式。

技術整合和運作現代化如何重塑診斷路徑並加強臨床和公共衛生環境中的病原體檢測。

腸道傳染病檢查領域正經歷著一場變革，其驅動力包括技術的成熟、工作流程的整合以及人們對監測日益成長的期望。分子診斷正從小眾的調查應用轉向一線臨床工具，聚合酵素鏈鎖反應(PCR) 的各種變體、恒溫環型核酸擴增(LAMP) 和即時PCR使得細菌、病毒和寄生蟲的檢測更加快速靈敏。同時，包括次世代定序和桑格定序在內的定序平台正被整合用於病原體鑑定、集體爆發追蹤和抗生素抗藥性分析，從而提升了數據分析和生物資訊學在常規臨床實踐中的作用。

評估 2025 年關稅變化將如何影響診斷產業所有相關人員的採購慣例、供應鏈彈性策略和資本規劃。

2025年關稅的引入和調整為腸道傳染病檢查領域的採購和供應鏈規劃帶來了新的複雜性。影響進口耗材、設備和某些檢查室組件的關稅調整迫使製造商和經銷商重新評估其籌資策略、調整定價模式並最佳化庫存緩衝，以維持偵測服務的連續性。這些措施對採購週期、資本支出計畫以及國內外商品的相對競爭格局產生了連鎖反應。

基於詳細細分的洞察，揭示了測試方法、產品線、最終用戶需求和病原體優先事項之間的交集，從而指導策略投資。

了解細分市場動態對於使產品開發和市場策略與用戶需求保持一致至關重要，這涵蓋了檢測方法、產品類型、最終用戶、病原體重點、檢體類型和分銷管道等各個方面。檢測方面的考慮範圍廣泛，從採用自動化和手動方法的傳統生化檢測，到包括非選擇性和選擇性培養基在內的培養技術，再到涵蓋化學化學冷光、酵素免疫分析法吸附試驗和側向流動免疫分析等免疫檢測方法。分子診斷透過恒溫環型核酸擴增、常規PCR和即時PCR平台提供獨特的價值提案，而從Sanger定序到次世代定序定序方案則支援對病原體進行詳細的表徵和監測。

將促進診斷方法採用差異化的區域趨勢進行比較，影響採購管道，並塑造供應鏈韌性策略。

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的部署模式、監管流程和供應鏈結構有顯著影響。在美洲，臨床檢查室和醫院系統通常優先考慮快速分子診斷和高通量儀器，以應對大量患者和支持疫情爆發，而監管核准和報銷機制則影響新檢測方法的部署速度。此外，該地區的檢測網路正在投資定序能力以進行監測，從而推動了對耗材和生物資訊解決方案的需求。

市場參與企業透過整合解決方案、策略夥伴關係和以數據為中心的服務來脫穎而出，並實現了持續的臨床應用。

腸道傳染病檢查市場的主要企業正致力於開發整合儀器、耗材和數位化服務的整合解決方案，以提高客戶維繫和生命週期價值。擁有成熟免疫檢測和分子診斷產品組合的公司正在投資自動化和互聯互通技術，以減少工作量並提高結果的可重複性。同時，定序供應商正在開發樣品製備盒和簡化的生物資訊流程，以降低技術應用門檻。小規模的創新公司則專注於快速照護現場橫向流動化驗、等溫擴增試劑盒或針對難培養標靶的專用培養基等細分領域。

採取切實可行的策略措施，增強製造商和醫療保健系統的韌性，加快部署，並帶來可衡量的營運和臨床效益。

產業領導企業應採取果斷行動，強化價值鏈，加速數位整合，並使產品系列與終端用戶的實際工作流程相契合。首先，供應商多元化和建立緊急庫存策略可以降低貿易中斷和關稅波動帶來的風險。其次，投資於儀器、檢查室資訊系統和分析平台之間的無縫資料整合，將提高營運效率，並提升高成本儀器的價值提案。

嚴謹的混合方法研究框架，結合相關人員訪談、技術文獻綜述和來自多個資訊來源的檢驗，確保了可靠的見解。

本分析的調查方法結合了定性和定量方法，旨在全面了解腸道傳染病檢查的發展趨勢。主要工作包括對實驗室負責人、臨床微生物學家、採購負責人和產品經理進行結構化訪談，以了解實際限制、推廣應用促進因素和技術偏好。此外，與分銷合作夥伴和服務機構的補充討論也提供了有關物流、價格壓力和售後支援模式的背景資訊。

整合技術、營運和策略主題，以突顯實現對腸道感染疾病進行穩健、快速診斷的途徑，滿足臨床和公共衛生需求。

腸道傳染病檢查領域的特點是技術快速發展、操作複雜以及市場瞬息萬變帶來的壓力，所有這些因素都要求相關人員具備清晰的策略方向。雖然傳統方法在病原體檢測和抗藥性分析中仍然發揮著至關重要的作用，但分子診斷和定序技術已成為及時檢測和流行病學調查的必要手段。耗材、設備、軟體和服務如今構成了一個相互依存的生態系統，其中一個領域的決策會影響其他領域的整體績效和價值實現。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 腸道疾病檢測市場（依檢測方法分類）

  • 生物化學檢驗
    • 自動生化分析
    • 手工生物化學檢驗
  • 培養方法
    • 非選擇性培養
    • 選擇性培養
  • 免疫檢測
    • 化學冷光免疫檢測
    • 酵素免疫分析法
    • 橫向流動化驗
  • 分子診斷
    • 恒溫環型核酸擴增
    • 聚合酵素鏈鎖反應
    • 即時聚合酵素鏈鎖反應
  • 定序
    • 次世代定序
    • 桑格定序

第9章：腸道疾病檢測市場：依產品類型分類

  • 消耗品
    • 成套工具
    • 試劑
  • 裝置
    • 免疫分析儀
    • 聚合酵素鏈鎖反應（PCR）裝置
    • 序列器
  • 軟體服務
    • 數據分析軟體
    • 維護服務

第10章：以病原體分類的腸道疾病檢測市場

  • 細菌病原體
    • 曲狀桿菌
    • 大腸桿菌
    • 沙門氏菌
  • 寄生病原體
  • 病毒病原體
    • 腺病毒
    • 諾羅病毒
    • 輪狀病毒

第11章 腸道疾病檢測市場：檢體類型

  • 血液檢體
  • 直腸拭子
  • 糞便檢體

第12章：腸道疾病檢測市場：依最終用戶分類

  • 學術和臨床檢查室
  • 診斷檢測實驗室
  • 醫院
  • 研究機構

第13章：腸道疾病檢測市場：依通路分類

  • 直銷
  • 銷售代理
  • 線上銷售

第14章：腸道疾病檢測市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：腸道疾病檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 腸道疾病檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國腸道疾病檢測市場

第18章：中國腸道疾病檢測市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 3M Company
  • Abbott Laboratories
  • ALS Limited
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biomerica, Inc.
  • bioMerieux SA
  • Bureau Veritas SA
  • Danaher Corporation
  • DiaSorin SpA
  • Eurofins Scientific SE
  • Hardy Diagnostics
  • Hologic, Inc.
  • Intertek Group plc
  • Merck KGaA
  • Meridian Bioscience, Inc.
  • Neogen Corporation
  • PerkinElmer, Inc.
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • QuidelOrtho Corporation
  • Roche Holding AG
  • Romer Labs Division Holding GmbH
  • SGS SA
  • Siemens Healthcare Diagnostics Inc.
  • TechLab, Inc.
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech plc
Product Code: MRR-732E7CFCB4A5

The Enteric Disease Testing Market was valued at USD 4.29 billion in 2025 and is projected to grow to USD 4.62 billion in 2026, with a CAGR of 8.29%, reaching USD 7.49 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.29 billion
Estimated Year [2026] USD 4.62 billion
Forecast Year [2032] USD 7.49 billion
CAGR (%) 8.29%

A comprehensive orientation to the evolving enteric disease testing environment where technology, regulation, and clinical needs converge to shape diagnostic strategy

Enteric disease testing sits at the intersection of clinical urgency and technological innovation, driven by the need to rapidly detect and respond to bacterial, viral, and parasitic outbreaks. Diagnostic laboratories, hospitals, research institutes, and academic centers rely on an increasingly diverse toolkit that includes biochemical testing, culture-based approaches, immunoassays, molecular diagnostics, and sequencing technologies. In parallel, evolving regulatory frameworks, changing reimbursement environments, and shifting patient pathways are reshaping how assays are validated, adopted, and integrated into routine workflows.

Today's testing ecosystem balances legacy methods such as selective and non-selective culture with modern modalities like real-time polymerase chain reaction and next-generation sequencing. This hybrid landscape requires laboratory managers and clinical leaders to evaluate trade-offs between throughput, sensitivity, turnaround time, and cost of ownership. As a result, purchasing decisions are less about replacing one technology with another and more about creating complementary diagnostic pathways that optimize patient care and surveillance capabilities.

Moreover, the proliferation of multiplex assays, rapid lateral flow formats, and data analysis software is expanding the operational footprint of enteric testing. Consequently, organizations must navigate procurement complexity, training needs, and data management challenges while preserving diagnostic quality and complying with accreditation standards. This introduction frames a marketplace where scientific rigor meets operational pragmatism, and where strategic choices will determine resilience against the next wave of enteric threats.

How technological convergence and operational modernization are redrawing diagnostic pathways and strengthening pathogen detection across clinical and public health settings

The landscape of enteric disease testing is undergoing transformative shifts driven by technological maturation, workflow consolidation, and heightened surveillance expectations. Molecular diagnostics have transitioned from niche research applications to frontline clinical tools, with polymerase chain reaction variants, loop mediated isothermal amplification, and real-time PCR enabling faster, more sensitive detection of bacterial, viral, and parasitic targets. At the same time, sequencing platforms, including next-generation and Sanger approaches, are being integrated for pathogen characterization, outbreak tracing, and antimicrobial resistance profiling, which elevates the role of data analytics and bioinformatics in routine practice.

Concurrently, immunoassays have diversified, as chemiluminescence assays, enzyme linked immunosorbent formats, and lateral flow devices expand point-of-care and laboratory-based testing options. Culture methods remain indispensable for isolate recovery and susceptibility testing, but laboratories increasingly combine culture with rapid molecular confirmation to accelerate case management. The rise of instrument automation and integrated consumable systems is reducing manual workloads, while software and maintenance services are becoming core components of procurement conversations.

These technological shifts are mirrored by operational and market dynamics. End users such as diagnostic laboratories, hospitals, research entities, and academic centers are reconfiguring workflows to accommodate multiplex testing and high-throughput sequencing. Distribution channels are adapting accordingly, with direct sales, distributors, and online platforms each playing distinct roles in meeting demand. Together, these changes are redefining how public health agencies and clinical providers detect, report, and respond to enteric threats.

Assessment of how tariff shifts in 2025 reshaped procurement practices, supply chain resilience strategies, and capital planning across diagnostic stakeholders

The introduction and adjustment of tariffs in 2025 have added a new layer of complexity to procurement and supply chain planning for enteric disease testing. Tariff adjustments affecting imported consumables, instruments, and certain laboratory components have compelled manufacturers and distributors to reassess sourcing strategies, adjust pricing models, and optimize inventory buffers to preserve continuity of testing services. These measures have had ripple effects across procurement cycles, capital expenditure planning, and the relative competitiveness of domestically produced versus imported goods.

Laboratories reliant on specialized reagents, kits, and sequencing consumables experienced pressure to identify alternative vendors or to negotiate long-term supply agreements that mitigate exposure to cost fluctuations. Instrument manufacturers responded by reengineering bills of materials, localizing certain production steps where feasible, and enhancing service offerings to justify total cost of ownership under new tariff environments. Furthermore, distributors diversified logistics routes and consolidated shipments to manage landed costs more effectively.

The tariffs also influenced the strategic calculus for end users considering capital investments. Hospitals and reference labs evaluated the trade-offs between leasing and purchasing equipment, and some accelerated procurement ahead of tariff implementations to avoid near-term cost increases. In parallel, software and maintenance services became more prominent as organizations sought to extract additional value from existing assets rather than pursue immediate hardware upgrades. Overall, the cumulative impact of tariffs has reinforced the importance of supply chain resilience, vendor diversification, and value-based procurement in sustaining enteric testing capabilities.

Deep segmentation-driven insights revealing where test method, product offerings, end-user needs, and pathogen priorities intersect to guide strategic investments

Understanding segmentation dynamics is essential to match product development and go-to-market strategies with user needs across test method, product type, end user, pathogen focus, sample type, and distribution channels. Test method considerations range from traditional biochemical tests with automated and manual approaches to culture techniques encompassing non-selective and selective media, as well as immunoassays spanning chemiluminescence, enzyme linked immunosorbent, and lateral flow formats. Molecular diagnostics present distinct value propositions through loop mediated isothermal amplification, conventional PCR, and real-time PCR platforms, while sequencing options from Sanger to next-generation sequencing support in-depth pathogen characterization and surveillance.

On the product side, consumables such as kits and reagents are core to day-to-day operations, whereas instruments including immuno analyzers, PCR machines, and sequencers represent capital investments that define throughput and capability. Complementing these are software and services, particularly data analysis tools and maintenance programs, which extend instrument uptime and translate raw outputs into actionable insights. End users span academic and clinical laboratories, diagnostic reference centers, hospitals, and research institutes, each with differing procurement cycles, regulatory requirements, and performance expectations.

Pathogen-specific segmentation underscores distinct assay design and clinical priorities: bacterial pathogens like Campylobacter, Escherichia coli, and Salmonella require both culture and molecular confirmation; viral targets such as adenovirus, norovirus, and rotavirus shift emphasis toward sensitive molecular and immunoassay detection; parasitic organisms demand specialized sample processing protocols. Sample types including blood, rectal swabs, and stool each impose upstream handling and nucleic acid extraction considerations that influence assay selection and workflow design. Finally, distribution channels-direct sales, distributors, and online platforms-shape lead times, service levels, and customer engagement models. Mapping these segments against one another reveals where integrated solutions, bundled consumable-instrument-service offerings, and targeted product enhancements can unlock clinical and operational value.

Comparative regional dynamics that drive differentiated adoption of diagnostics, influence procurement pathways, and shape supply chain resilience strategies

Regional dynamics materially influence adoption patterns, regulatory pathways, and supply chain configurations across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, clinical laboratories and hospital systems often prioritize rapid molecular diagnostics and high-throughput instruments to manage large patient volumes and support outbreak response, while regulatory approvals and reimbursement mechanisms shape the cadence of new test introductions. Laboratory networks in this region also invest in sequencing capabilities for surveillance, which drives demand for consumables and bioinformatics solutions.

Across Europe Middle East & Africa, diverse regulatory environments and heterogeneous healthcare infrastructures create differentiated opportunities for both centralized reference laboratories and decentralized testing models. In many countries, stringent validation requirements underscore the importance of certified reagents and accredited workflows, whereas public health priorities steer investment toward multiplex assays and platforms capable of integrating surveillance data. Distribution strategies must account for complex logistics across multiple jurisdictions and varying procurement practices.

The Asia-Pacific region presents a mix of highly advanced urban centers and rapidly developing laboratory markets, leading to simultaneous demand for cutting-edge sequencing and scalable immunoassay platforms. Local manufacturing hubs in some countries influence supply chain resilience and cost structures, and partnerships with regional distributors can accelerate market access. In all regions, collaborative public-private initiatives, cross-border surveillance programs, and regional procurement frameworks increasingly shape how enteric testing resources are allocated and deployed.

How market participants are differentiating through integrated offerings, strategic partnerships, and data-centric services to capture sustained clinical adoption

Major players across the enteric testing landscape are focusing on integrated solutions that combine instruments, consumables, and digital services to enhance customer retention and lifecycle value. Companies with established immunoassay and molecular portfolios are investing in automation and connectivity to reduce hands-on time and improve result reproducibility, while sequencing providers are advancing library preparation kits and streamlined bioinformatics pipelines to lower technical barriers for adoption. Smaller innovators are concentrating on niche areas such as rapid point-of-care lateral flow assays, isothermal amplification kits, or specialized media for challenging culture targets.

Strategic activity includes partnerships to expand distribution footprints, co-development agreements to accelerate assay validation, and after-sales service enhancements to improve uptime and customer satisfaction. Several firms emphasize hybrid go-to-market models that blend direct engagement with channel partnerships to address heterogeneous end-user preferences. There is also a clear trend toward subscription and service-based offerings that bundle consumables with instruments and software, thereby smoothing revenue streams and deepening customer relationships.

Competitive differentiation increasingly hinges on data capabilities, including interoperability with laboratory information systems, robust data analysis software, and services that translate complex sequencing outputs into clinically relevant intelligence. As stakeholders prioritize rapid diagnostics, scalability, and actionable insights, companies that can deliver end-to-end solutions and demonstrate measurable operational benefits will secure stronger positions in the market.

Actionable strategic moves for manufacturers and health systems to bolster resilience, accelerate adoption, and deliver measurable operational and clinical benefits

Industry leaders should act decisively to strengthen supply chains, accelerate digital integration, and align product portfolios with end-user workflow realities. First, diversifying supplier bases and establishing contingency inventory strategies will mitigate exposure to trade disruptions and tariff volatility. Second, investing in seamless data connectivity between instruments, laboratory information systems, and analytics platforms will unlock operational efficiencies and enhance the value proposition of higher-cost instrumentation.

Third, manufacturers and distributors should consider modular commercial models that combine consumables, instruments, and software services into subscription plans, which can lower barriers to entry for resource-constrained laboratories while providing predictable revenue streams. Fourth, prioritizing assay development that balances sensitivity, turnaround time, and ease of use-especially for common enteric pathogens like Campylobacter, Escherichia coli, Salmonella, norovirus, and rotavirus-will meet both clinical and public health needs. Fifth, targeted investments in training, technical support, and maintenance services will preserve uptime and improve customer satisfaction, particularly in regions with varied laboratory capabilities.

Finally, fostering collaborative relationships with academic centers, public health agencies, and hospital networks will enable co-development of surveillance-focused solutions and validation studies. By implementing these actions, industry leaders can enhance resilience, accelerate adoption of transformative diagnostics, and deliver measurable benefits across clinical and laboratory settings.

A rigorous mixed-methods research framework integrating stakeholder interviews, technical literature review, and cross-source triangulation to ensure credible insights

The research methodology underpinning this analysis combined qualitative and quantitative approaches to gather a comprehensive view of enteric disease testing dynamics. Primary engagements included structured interviews with laboratory directors, clinical microbiologists, procurement professionals, and product managers to capture real-world operational constraints, adoption drivers, and technology preferences. Supplementary discussions with distribution partners and service organizations provided context on logistics, pricing pressures, and after-sales support models.

Secondary research involved a systematic review of regulatory guidance, clinical practice standards, and recent peer-reviewed literature to ensure alignment with validated laboratory procedures and diagnostic performance expectations. Product literature, manufacturer technical specifications, and instrument service manuals were analyzed to evaluate throughput characteristics, consumable dependencies, and integration capabilities. Comparative analysis across test methods, product categories, and end-user types enabled identification of recurring themes, capability gaps, and commercialization pathways.

Data synthesis emphasized triangulation across sources to reconcile differing stakeholder perspectives and mitigate bias. Throughout the process, attention was paid to reproducibility, transparency in data sourcing, and the contextual relevance of findings to clinical laboratories, hospitals, research institutes, and academic centers. This mixed-methods approach supports robust, actionable insights while acknowledging the operational heterogeneity that characterizes enteric disease testing.

A synthesis of technological, operational, and strategic themes highlighting the path to resilient and responsive enteric diagnostics for clinical and public health needs

The enteric disease testing domain is characterized by rapid technological progress, operational complexity, and evolving market pressures that together demand strategic clarity from stakeholders. Traditional methods continue to play a vital role in pathogen recovery and resistance profiling, while molecular and sequencing technologies have become indispensable for timely detection and epidemiologic investigation. Consumables, instruments, software, and services now form an interdependent ecosystem where decisions in one area influence performance and value realization across others.

Regional nuances, tariff-driven procurement adjustments, and the need for resilient distribution strategies underscore the importance of flexible commercial models and strong after-sales capabilities. End users-from centralized reference laboratories to point-of-care settings-require tailored solutions that account for sample types, pathogen targets, and throughput needs. Companies that offer integrated, data-enabled solutions and that invest in partnerships and local support structures will be best positioned to meet these diverse requirements.

Looking ahead, the sector's trajectory will be shaped by continued innovation in assay chemistry, automation, and bioinformatics, alongside concerted efforts to build supply chain resilience and regulatory alignment. The cumulative effect will be a more responsive diagnostic infrastructure that better supports clinical decision-making and public health surveillance for enteric diseases.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Enteric Disease Testing Market, by Test Method

  • 8.1. Biochemical Tests
    • 8.1.1. Automated Biochemical Analysis
    • 8.1.2. Manual Biochemical Tests
  • 8.2. Culture Methods
    • 8.2.1. Non Selective Culture
    • 8.2.2. Selective Culture
  • 8.3. Immunoassays
    • 8.3.1. Chemiluminescence Immunoassay
    • 8.3.2. Enzyme Linked Immunosorbent Assay
    • 8.3.3. Lateral Flow Assay
  • 8.4. Molecular Diagnostics
    • 8.4.1. Loop Mediated Isothermal Amplification
    • 8.4.2. Polymerase Chain Reaction
    • 8.4.3. Real Time Polymerase Chain Reaction
  • 8.5. Sequencing
    • 8.5.1. Next Generation Sequencing
    • 8.5.2. Sanger Sequencing

9. Enteric Disease Testing Market, by Product Type

  • 9.1. Consumables
    • 9.1.1. Kits
    • 9.1.2. Reagents
  • 9.2. Instruments
    • 9.2.1. Immuno Analyzers
    • 9.2.2. Polymerase Chain Reaction Instruments
    • 9.2.3. Sequencers
  • 9.3. Software & Services
    • 9.3.1. Data Analysis Software
    • 9.3.2. Maintenance Services

10. Enteric Disease Testing Market, by Pathogen

  • 10.1. Bacterial Pathogens
    • 10.1.1. Campylobacter
    • 10.1.2. Escherichia Coli
    • 10.1.3. Salmonella
  • 10.2. Parasitic Pathogens
  • 10.3. Viral Pathogens
    • 10.3.1. Adenovirus
    • 10.3.2. Norovirus
    • 10.3.3. Rotavirus

11. Enteric Disease Testing Market, by Sample Type

  • 11.1. Blood Samples
  • 11.2. Rectal Swabs
  • 11.3. Stool Samples

12. Enteric Disease Testing Market, by End User

  • 12.1. Academic And Clinical Laboratories
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals
  • 12.4. Research Institutes

13. Enteric Disease Testing Market, by Distribution Channel

  • 13.1. Direct Sales
  • 13.2. Distributors
  • 13.3. Online Sales

14. Enteric Disease Testing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Enteric Disease Testing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Enteric Disease Testing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Enteric Disease Testing Market

18. China Enteric Disease Testing Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. 3M Company
  • 19.6. Abbott Laboratories
  • 19.7. ALS Limited
  • 19.8. Becton, Dickinson and Company
  • 19.9. Bio-Rad Laboratories, Inc.
  • 19.10. Biomerica, Inc.
  • 19.11. bioMerieux SA
  • 19.12. Bureau Veritas SA
  • 19.13. Danaher Corporation
  • 19.14. DiaSorin S.p.A.
  • 19.15. Eurofins Scientific SE
  • 19.16. Hardy Diagnostics
  • 19.17. Hologic, Inc.
  • 19.18. Intertek Group plc
  • 19.19. Merck KGaA
  • 19.20. Meridian Bioscience, Inc.
  • 19.21. Neogen Corporation
  • 19.22. PerkinElmer, Inc.
  • 19.23. QIAGEN N.V.
  • 19.24. Quest Diagnostics Incorporated
  • 19.25. QuidelOrtho Corporation
  • 19.26. Roche Holding AG
  • 19.27. Romer Labs Division Holding GmbH
  • 19.28. SGS SA
  • 19.29. Siemens Healthcare Diagnostics Inc.
  • 19.30. TechLab, Inc.
  • 19.31. Thermo Fisher Scientific Inc.
  • 19.32. Trinity Biotech plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENTERIC DISEASE TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ENTERIC DISEASE TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY TEST METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PATHOGEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ENTERIC DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ENTERIC DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY AUTOMATED BIOCHEMICAL ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY AUTOMATED BIOCHEMICAL ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY AUTOMATED BIOCHEMICAL ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MANUAL BIOCHEMICAL TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MANUAL BIOCHEMICAL TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MANUAL BIOCHEMICAL TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NON SELECTIVE CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NON SELECTIVE CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NON SELECTIVE CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SELECTIVE CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SELECTIVE CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SELECTIVE CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY LOOP MEDIATED ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNO ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNO ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNO ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MAINTENANCE SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MAINTENANCE SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY MAINTENANCE SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CAMPYLOBACTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CAMPYLOBACTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY CAMPYLOBACTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ESCHERICHIA COLI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ESCHERICHIA COLI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ESCHERICHIA COLI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SALMONELLA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SALMONELLA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SALMONELLA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PARASITIC PATHOGENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PARASITIC PATHOGENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY PARASITIC PATHOGENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NOROVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NOROVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY NOROVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ROTAVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ROTAVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ROTAVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BLOOD SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BLOOD SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY BLOOD SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RECTAL SWABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RECTAL SWABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RECTAL SWABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY STOOL SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY STOOL SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY STOOL SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ACADEMIC AND CLINICAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ACADEMIC AND CLINICAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ACADEMIC AND CLINICAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ONLINE SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS ENTERIC DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA ENTERIC DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE ENTERIC DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. MIDDLE EAST ENTERIC DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. AFRICA ENTERIC DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, 2018-2032 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC ENTERIC DISEASE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 293. GLOBAL ENTERIC DISEASE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 294. ASEAN ENTERIC DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 295. ASEAN ENTERIC DISEASE TESTING MARKET SIZE, BY TEST METHOD, 2018-2032 (USD MILLION)
  • TABLE 296. ASEAN ENTERIC DISEASE TESTING MARKET SIZE, BY BIOCHEMICAL TESTS, 2018-2032 (USD MILLION)
  • TABLE 297. ASEAN ENTERIC DISEASE TESTING MARKET SIZE, BY CULTURE METHODS, 2018-2032 (USD MILLION)
  • TABLE 298. ASEAN ENTERIC DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 299. ASEAN ENTERIC DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 300. ASEAN ENTERIC DISEASE TESTING MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 301. ASEAN ENTERIC DISEASE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. ASEAN ENTERIC DISEASE TESTING MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 303. ASEAN ENTERIC DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 304. ASEAN ENTERIC DISEASE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 305. ASEAN ENTERIC DISEASE TESTING MARKET SIZE, BY PATHOGEN, 2018-2032 (USD MILLION)
  • TABLE 306. ASEAN ENTERIC DISEASE TESTING MARKET SIZE, BY BACTERIAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 307. ASEAN ENTERIC DISEASE TESTING MARKET SIZE, BY VIRAL PATHOGENS, 2018-2032 (USD MILLION)
  • TABLE 308. ASEAN ENTERIC DISEASE TESTIN